. Author manuscript; available in PMC: 2018 Feb 1.

Published in final edited form as: J Allergy Clin Immunol. 2016 Jun 16;139(2):628–633.e10. doi: 10.1016/j.jaci.2016.04.049

Table 3.

Incidence and Relative Risk of aGVHD, cGVHD.

All Patients	N (%)	TME(+) N (%)	TME(−) N (%)	RR (95%CI)	p
	74	35	39
aGVHD I–IV	27 (36.5)	20 (57.1)	7 (17.9)	3.2 (1.5–6.6)	0.0007
aGVHD II–IV	21 (28.4)	15 (42.9)	6 (15.4)	2.8 (1.2–6.4)	0.011
aGVHD III–IV	7 (9.5)	5 (14.3)	2 (5.1)	2.8 (0.58–13)	0.24
cGVHD (N=35, 37)^{^}	6 (8.1)	4 (11.4)	2 (5.4)	2.1 (0.41–11)	0.42

^{^}

2 patients in the TME(−) group were not evaluable for cGVHD.